Medical Weight Loss Center
Medical Weight Loss Center · 250 Pierce Street · Kingston, PA 18704
5.0· 3 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Medical Weight Loss Center is a weight-loss practice in Kingston, Pennsylvania. Per its website, the center believes body weight, eating habits and lifestyle all shape a person's weight-loss journey, recommends programs it thinks patients can stick with, and starts with a comprehensive intake consultation covering a blood test, measurements, a weigh-in and a physical exam. It holds a 5.0-star Google rating across 3 reviews, the first from 2016 and none in the past year, with one review mentioning the staff and one mentioning results.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2019-08-11. Read the reviews themselves on the practice's Google listing.
What patients say
This practice holds a ★5.0 Google rating across 3 reviews. 100% of the 3 reviews we analyzed are 5-star. reviewers most often mention staff & front desk (1), results (1).
Most recent Google reviews
Alice R.★★★★★2019-08-11I lost 114 lbs and the staff is very helpful and really care.
Reviews and counts are from this practice's public Google Business listing and reflect their authors' opinions, not RetaMaps'. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs